Chouela 1999.

Methods	Design: randomized controlled trial Generation of allocation sequence: unclear Allocation concealment: unclear Blinding: participants (study described as double blind) Inclusion of randomized participants in the analysis: 81% (10/53 participants lost to follow up or withdrew)
Participants	Number: 53 enrolled (aged over 18 years with a mean age of 40.8 years; 19 males, 34 females) Inclusion criteria: clinical or parasitological signs compatible with scabies Exclusion criteria: pregnancy; breastfeeding; treatment for scabies within previous 4 weeks; renal dysfunction; hepatic dysfunction; concomitant antidepressant; anxiolytic or antipruritic drug use; severe immunodeficiency; HIV infection; clinically high risk for HIV; neoplasia affecting immunity; immunosuppressive treatment; gastrointestinal dysfunction; history of convulsions
Interventions	1. Single dose of oral ivermectin, 150 to 200 µg/kg in 6 mg tablets plus single topical application of 60 mL placebo solution (26 participants) 2. Single topical application of 60 mL 1% lindane topical solution plus placebo tablets (27 participants) Both placebo and 1% lindane solutions applied neck to toe and kept on for 8 h Not included in this review: 3. Second dose of oral ivermectin, 150 to 200 µg/kg in 6 mg tablets plus single topical application of 60 mL placebo solution at 15 days for treatment failures in intervention group 1 (ivermectin) 4. Second topical application of 60 mL 1% lindane topical solution plus placebo tablets at 15 days for treatment failures in intervention group 2 (lindane)
Outcomes	1. Number of participants cured at 15 days (defined as absence of pruritus and clinical lesions or a reduction of signs and symptoms to a score of 1 (mild pruritus and mild lesions)) 2. Adverse events Not included in this review 3. Number of participants receiving second dose at 15 days who were cured at 29 days
Notes	Location: Argentina Date: April 1996 to February 1997 Members of the same household who were infested but could not be included in the study treated with 1% lindane (adults) or 6% sulfur cream (infants)